Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table-Reference-Cited by-同舟云学术

Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table

Published:2014-08 Issue:2 Volume:28 Page:149-153
ISSN:1094-5539
Container-title:Pulmonary Pharmacology & Therapeutics
language:en
Short-container-title:Pulmonary Pharmacology & Therapeutics

Author:

Kornmann Oliver,Watz Henrik,Fuhr Rainard,Krug Norbert,Erpenbeck Veit J.,Kaiser Guenther

Funder

Novartis Pharma AG

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biochemistry, medical,Pulmonary and Respiratory Medicine

Reference15 articles.

1. Targeting IgE in asthma;Kuhl;Curr Opin Pulm Med,2012

2. European Medicines Agency (EMA): Omalizumab (Xolair®) full prescribing information (EU). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf [accessed 13.04.13]

3. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma;Bousquet;Allergy,2005

4. Safety and tolerability of omalizumab;Corren;Clin Exp Allergy,2009

5. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE;Humbert;Allergy,2005

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Omalizumab in severe asthma and food allergies with IgE levels >1500 kU/L: Two‐year evaluation;Pediatric Allergy and Immunology;2023-12

2. Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL;World Allergy Organization Journal;2023-06

3. Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis;The Journal of Allergy and Clinical Immunology: In Practice;2023-05

4. Research progress of omalizumab in the treatment of bullous pemphigoid;The Journal of Dermatology;2023-03-27

5. IgE-immunoadsorption for severe allergy to multiple foods: A case series of five children;World Allergy Organization Journal;2023-02